Investors are keeping a close eye on inflation and interest rates. Goldman Sachs shared 21 growth stocks that can soar if ...

Shares of Fulcrum Therapeutics (FULC) jumped 7% post-market after Goldman Sachs upgraded the stock to buy and raised peak ...

Goldman Sachs Chief U.S. Equity Strategist David Kostin sees “no return” coming for stocks in the remainder of the year, ...

The banking sector is in a unique time and place as investors navigate economic conditions, such as higher for longer ...

Solomon said that while it was anticipated that the government would spend during COVID lockdowns, “we’re a long way out of ...

Oil company Chevron was the most shorted U.S. stock in April, overtaking long-standing top target Tesla as short-sellers up ...

Simultaneously, JMP Securities analysts also assumed coverage on IBTA, with a Market Outperform rating and a $130 price target. The investment firm believes that the technology company is transforming ...

InvestingPro is fiving a fair value of INR 432 per share foe HPCL and INR 593 per share for BPCL. While Goldman Sachs is ...

Forecasts suggest a low single-digit volume growth for JLR in FY25 as the order backlog stabilizes. While April showed ...

Jamf (Nasdaq: JAMF), the standard in managing and securing Apple at work, today announced the pricing of an underwritten ...

Fintel reports that on May 13, 2024, Goldman Sachs upgraded their outlook for Fulcrum Therapeutics ( NasdaqGM:FULC) from Neutral to Buy.

Fintel reports that on May 13, 2024, Goldman Sachs upgraded their outlook for CG Oncology (NasdaqGS:CGON) from Neutral to Buy. As of May 8, 2024, the average one-year price target for CG Oncology is ...